Canada Biosurgery Market Overview, 2031

Key Insights
• The Canada biosurgery market represents a sophisticated and steadily growing segment within the broader North American medical device landscape. Valued at approximately USD 540 million in 2025, the Canadian market represents the second-largest national market in North America American biosurgery market and serves as a critical market for major global biosurgery manufacturers. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.
• Hemostatic agents represent the second largest product category within the Canadian biosurgery market, driven by their essential application across all surgical specialties. The aging Canadian population and increasing prevalence of chronic conditions requiring surgical intervention continue to drive demand for advanced bleeding control solutions.Bone-graft substitutes constitute a major market pillar, supported by the high volume of hip and knee replacements, spinal fusion procedures, and orthopedic trauma surgeries performed annually across Canadian hospitals. The Canadian Institute for Health Information (CIHI) reports that in 2024, there were 26% more hip replacements and 21% more knee replacements completed across Canada than in 2019.
• The regulatory environment, centered on Health Canada's Medical Devices Directorate and the risk-based classification system for medical devices, plays a decisive role in shaping market dynamics. Health Canada licenses determine product availability, while provincial health authority procurement policies directly influence adoption rates across hospital and ambulatory settings.The Canadian market is experiencing a steady recovery in surgical volumes following the COVID-19 pandemic, with surgical procedures now exceeding pre-pandemic levels. However, wait times for priority procedures including hip and knee replacements, cataract surgeries, and cancer surgeries remain longer than before the pandemic, creating both challenges and opportunities for the biosurgery market.

Market Outlook
• According to the Bonafide research report, “Canada Biosurgery market Outlook, 2031,” published by Bonafide Research, the Canada Biosurgery market was valued at more than 540 Million in 2025. supported by favorable demographic trends, ongoing healthcare infrastructure investment, and expanding surgical volumes across both inpatient and outpatient settings.
• The market's growth trajectory is intrinsically linked to the broader Canadian healthcare landscape, including provincial health budgets, surgical capacity expansion initiatives, and the pace of adoption of minimally invasive surgical technologies.
• Canada's healthcare expenditure continues to rise steadily, reaching approximately CAD 398.8 billion in 2025, representing 12.7% of GDP. This translates to approximately CAD 9,626 per capita, with hospitals accounting for 26.0% of total health spending. This substantial healthcare investment provides the foundation for sustained surgical activity and biosurgical product utilization.
• The aging Canadian population represents the most significant long-term demand driver. As of July 1, 2025, 19.5% of Canada's population is aged 65 years and older, with the median age reaching 40.6 years. As this demographic cohort continues to expand, the incidence of degenerative joint diseases, spinal disorders, cardiovascular conditions, and cancers requiring surgical intervention will rise correspondingly, driving sustained demand for biosurgical products across all major categories.
• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. Health Canada has licensed advanced robotic-assisted surgery systems, including Medtronic's Hugo™ system for urologic and gynecologic laparoscopic procedures. These next-generation surgical platforms create new opportunities for biosurgical products specifically designed for minimally invasive and robotic procedures.
• The reduction of surgical wait times remains a key priority for federal and provincial governments. CIHI data indicates that while more surgeries are being performed than before the pandemic, wait times have grown longer. This surgical backlog represents a significant opportunity for biosurgery manufacturers, as increased procedure volumes will directly drive demand for hemostatic agents, sealants, and bone-graft substitutes.
Market Dynamics
Driver: Growing Surgical Volumes and Aging Population The Canadian biosurgery market benefits from consistently high surgical volumes across all major specialties, driven by an aging population and increasing prevalence of chronic diseases. CIHI reports that in 2024, there were 26% more hip replacements, 21% more knee replacements, 11% more cataract surgeries, and 7% more cancer surgeries completed across Canada than in 2019. With 19.5% of Canadians aged 65 and older as of July 2025, the demand for orthopedic, cardiovascular, and cancer surgeries will continue to rise. Healthcare expenditure in Canada reached CAD 398.8 billion in 2025, representing 12.7% of GDP, with hospitals accounting for 26.0% of total health spending, providing the financial infrastructure to support expanding surgical volumes. This combination of demographic pressure and sustained healthcare investment creates a robust demand environment for biosurgical products.

Challenge: Surgical Wait Times and Capacity Constraints Despite increasing surgical volumes, the Canadian healthcare system faces significant capacity constraints that limit the full potential of the biosurgery market. According to CIHI data, wait times for priority procedures remain longer than before the pandemic, with one in 10 Nova Scotians still waiting 374 days for a knee replacement and 289 days for a hip replacement in 2025. The Fraser Institute reports that the median wait time between referral by a general practitioner and receiving treatment reached approximately 28.6 weeks in 2025, with orthopedic and neurosurgical procedures often exceeding 45 weeks on average. These extended wait times reflect systemic capacity limitations including operating room availability, surgical workforce shortages, and hospital bed constraints that restrict the number of procedures that can be performed annually. For biosurgery manufacturers, this creates a ceiling on immediate revenue growth, as procedure volumes are constrained by healthcare system capacity rather than patient demand alone.

Trend: Increasing Adoption of Minimally Invasive and Robotic-Assisted Surgery The Canadian biosurgery market is experiencing a significant trend toward minimally invasive and robotic-assisted surgical techniques. Health Canada has licensed the Hugo™ robotic-assisted surgery system from Medtronic for use in urologic and gynecologic laparoscopic surgical procedures, which make up about half of all robotic procedures performed today. Canadian hospitals are increasingly adopting advanced surgical technologies, including Stryker's Mako robotic system for orthopedic procedures. This shift toward minimally invasive techniques creates new opportunities for biosurgical products specifically designed for robotic and laparoscopic applications. Surgical sealants and adhesives that can be delivered through small incisions, hemostatic agents optimized for sprayable application, and staple-line reinforcement products compatible with robotic staplers are increasingly in demand. The expansion of robotic-assisted surgery in Canada will continue to drive innovation and adoption in the biosurgery market.
Policies
• Health Canada regulates medical devices under the Food and Drugs Act and the Medical Devices Regulations (SOR/98-282). Medical devices are classified into four risk-based categories (Class I to IV), with biosurgical products typically falling under Class II (short-term invasive) or Class III (long-term invasive or surgically implanted) designations.
• Health Canada's risk-based classification system categorizes surgically invasive devices intended to be absorbed by the body or normally intended to remain in the body for at least 30 consecutive days as Class III, requiring more rigorous pre-market review. Devices containing biological material from animal or human tissue undergo additional assessment of risk mitigation measures.
• The Canadian Institute for Health Information (CIHI) is mandated to collect wait time information and monitor provincial progress in meeting benchmarks for five priority areas: cancer treatment, cardiac care, diagnostic imaging, joint replacement, and sight restoration. CIHI's wait time indicators directly influence provincial healthcare planning and surgical capacity expansion.
• Provincial health authorities manage hospital budgets and procurement decisions, with Group Purchasing Organizations (GPOs) playing an increasingly important role in biosurgical product selection and pricing. The consolidation of hospital procurement across provinces creates both opportunities and challenges for biosurgery manufacturers seeking market access.
• Health Canada's licensing of robotic-assisted surgery systems including Medtronic's Hugo™ system and Stryker's Mako platform reflects the agency's commitment to facilitating access to advanced surgical technologies. These regulatory approvals expand the addressable market for biosurgical products compatible with robotic surgical platforms.
• Federal and provincial healthcare investment continues to support surgical capacity expansion. With healthcare expenditure reaching CAD 398.8 billion in 2025 and hospitals accounting for 26.0% of total health spending, government commitment to healthcare infrastructure supports sustained biosurgery market growth.
Segment Analysis
Canada Biosurgery Market By Product • Hemostatic Agents represent the second largest product category within the Canadian biosurgery market, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding. The aging Canadian population and increasing prevalence of conditions requiring surgical intervention drive sustained demand for advanced hemostatic solutions.
• Bone-Graft Substitutes constitute a major market segment, supported by the high volume of hip and knee replacements, spinal fusion procedures, and orthopedic trauma surgeries. CIHI reports 26% more hip replacements and 21% more knee replacements in 2024 compared to 2019. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors.
• Surgical Sealants and Adhesives represent a dynamic and growing product category, driven by increasing adoption of minimally invasive and robotic surgical techniques across Canadian hospitals. These products are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses, with particular application in cardiovascular, thoracic, and general surgery.
• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines, reducing the risk of bleeding and leakage. The rising prevalence of obesity with self-reported obesity prevalence at 24% in Canada, higher than the OECD average of 19% continues to drive demand.
• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts. These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures supported by high procedure volumes.
• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention.

Canada Biosurgery Market By Application • Orthopedic Surgery is the largest application area for biosurgical products in Canada, driven by the high volume of hip and knee replacements, spinal fusion procedures, and orthopedic trauma surgeries. Bone-graft substitutes are the primary biosurgical products utilized, supplemented by hemostatic agents and soft-tissue attachments. CIHI data confirms that hip and knee replacements represent priority procedures with significant surgical volumes.
• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including bariatric surgery, colorectal surgery, and hernia repair. Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers.
• Cardiovascular Surgery represents a high-value application area for biosurgical products, including vascular sealants, hemostatic agents, and soft-tissue attachments. Cardiac care is one of five priority areas identified for wait time reduction, reflecting the importance of cardiovascular surgical procedures in Canada.
• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures. Wait times for neurosurgical procedures often exceed 45 weeks on average.
• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer. Cancer surgery is a priority area for wait time monitoring, reflecting its clinical importance.
• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery.
• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement in hysterectomies and other gynecological interventions.
• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications. Health Canada's licensing of the Hugo™ robotic-assisted surgery system for urologic laparoscopic procedures reflects the growing importance of this application area.



Canada Biosurgery Market By Source/Origin • Biologic products derived from human, animal, or microbial sources have traditionally dominated the Canadian biosurgery market due to their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. Health Canada's regulatory framework for devices containing biological material requires assessment of risk mitigation measures associated with animal or human tissue.
• Synthetic and Semi-Synthetic products are gaining share in the Canadian market due to cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. Provincial procurement policies increasingly favor cost-effective synthetic alternatives for certain applications.

Canada Biosurgery Market By End-User • Hospitals remain the largest end-user segment for biosurgical products in Canada, accounting for the majority of revenue. Hospitals account for 26.0% of total healthcare spending, reflecting their central role in surgical care delivery. The concentration of complex surgical procedures and availability of specialized surgical teams make hospitals the primary setting for biosurgical product utilization.
• Ambulatory Surgical Centers (ASCs) represent a growing end-user segment in Canada, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. CIHI has expanded its definition of surgery to include procedures performed in specialized treatment spaces like cardiac cath laboratories and interventional radiology suites. This expanded definition reflects the increasing volume of procedures performed outside traditional hospital operating rooms.
• Clinics represent a smaller but growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.

Canada Biosurgery Market Economics

• The Canadian biosurgery market operates within a publicly funded healthcare system characterized by provincial administration, centralized procurement, and cost-containment pressures. Understanding the economic drivers of the market is essential for manufacturers seeking to optimize their commercial strategies.
• Pricing and Reimbursement: Biosurgical products in Canada face pricing pressure from provincial health authorities and Group Purchasing Organizations (GPOs) that negotiate volume discounts. Unlike the U.S. market, where private insurance and Medicare provide multiple reimbursement pathways, the Canadian system operates through provincial health budgets that are subject to annual funding constraints. Healthcare expenditure reached CAD 398.8 billion in 2025, representing 12.7% of GDP, with hospitals accounting for 26.0% of total health spending. The public-sector share of total spending is 71.2%, reflecting the dominant role of government in healthcare financing. Manufacturers must demonstrate both clinical efficacy and cost-effectiveness to secure favorable procurement positions.
• Procurement and Supply Chain: Biosurgical products in Canada are procured through a combination of provincial health authority contracts, hospital system-level agreements, and GPO negotiations. The consolidation of hospital procurement across provinces has intensified pricing competition, particularly for commoditized products. Manufacturers must navigate complex procurement processes, demonstrating both clinical value and economic benefit to secure favorable contract positions. The Canadian supply chain is well-developed, with major manufacturers maintaining distribution networks across the country's provinces and territories. Baxter operates Canada's only large-scale manufacturing plant for life-sustaining intravenous and dialysis solutions in Alliston, Ontario.
• Manufacturing and Investment: Major biosurgery manufacturers maintain manufacturing, distribution, and commercial operations within Canada, benefiting from the country's skilled workforce, advanced manufacturing infrastructure, and stable business environment. Investment in Canadian operations is supported by the country's large and stable healthcare market, which provides a reliable revenue base. Recent years have seen continued investment in manufacturing automation, quality systems, and capacity expansion to meet growing demand. Baxter's Alliston facility represents a significant manufacturing investment in the Canadian healthcare sector.

Market Outlook by Infrastructure, Investment and Industry Development
• Healthcare Infrastructure: Canada has a comprehensive healthcare system supporting surgical care across hospitals and specialized facilities. Hospitals account for 26.0% of total health spending, while evolving surgical settings continue to expand access to procedures.
• Surgical Workforce: Canada has a highly trained surgical workforce, but capacity constraints contribute to long wait times, particularly for orthopedic and neurosurgical procedures. Workforce development and training will be critical to increasing surgical capacity.
• Investment in Innovation: Strong research institutions, teaching hospitals, and government funding support innovation in biosurgery. Investment continues in robotic surgery, advanced biomaterials, and next-generation surgical technologies.
• Regulatory Environment: Health Canada's risk-based medical device framework provides established pathways for market entry. Class III and biologically based devices undergo more rigorous safety and risk assessments.
• Technology Adoption: Canada is increasingly adopting robotic-assisted surgery, minimally invasive techniques, and advanced biomaterials. Recent licensing and clinical deployment of robotic platforms demonstrate continued technology adoption.
• Long-Term Growth Outlook: The Canadian biosurgery market has strong growth potential, supported by an aging population, rising healthcare expenditure, and expanding surgical needs. In 2025, 19.5% of Canadians were aged 65+, while healthcare spending reached CAD 398.8 billion, or 12.7% of GDP.


Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Biosurgery Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product
• Bone-Graft Substitutes
• Hemostatic Agents
• Surgical Sealants & Adhesives
• Adhesion Barriers
• Soft-Tissue Attachments
• Staple-Line Reinforcement

By Application:
• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery
• Urological Surgery
• Other surgeries (Thoracic surgeries & more)

By Source/Origin
• Biologic
• Synthetic / Semi-synthetic

By End-user:
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Others"